174 related articles for article (PubMed ID: 23992250)
1. Autoimmune haemophilia in a teenager.
Batra S; Sharathkumar A; Glaubach T; Gamerman S; Green D
Haemophilia; 2013 Nov; 19(6):e386-8. PubMed ID: 23992250
[No Abstract] [Full Text] [Related]
2. Successful eradication of inhibitor in a patient with severe haemophilia B and anaphylaxis to factor IX concentrates: is there a role for Rituximab and desensitization therapy?
Gamerman S; Singh AM; Makhija M; Sharathkumar A
Haemophilia; 2013 Nov; 19(6):e382-5. PubMed ID: 23992223
[No Abstract] [Full Text] [Related]
3. [Acquired haemophilia: From registers' data to therapeutic recommendations].
Lévesque H
Rev Med Interne; 2013 Jan; 34(1):1-3. PubMed ID: 22998977
[No Abstract] [Full Text] [Related]
4. Successful treatment of a patient with acquired haemophilia A with a combination of a low-dose rituximab and recombinant human FVIIa.
Xu Y; Zhang X; Zhao Y; Zhao L; Qiu H; Wu D
Haemophilia; 2013 Mar; 19(2):e95-6. PubMed ID: 23231056
[No Abstract] [Full Text] [Related]
5. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
6. Efficacy of rituximab in acquired factor XIII inhibitor after arterial rFVIIa-induced thrombosis.
Ngo Sack F; Galinat H; Egreteau PY; Mollard LM; Fortin H; Berthou C; Abgrall JF; Pan-Petesch B
Haemophilia; 2013 Mar; 19(2):e93-4. PubMed ID: 23205641
[No Abstract] [Full Text] [Related]
7. Acquired hemophilia: a clinical experience.
Mirza MA; Khimani F; Rogers J
W V Med J; 2010; 106(7):32-5. PubMed ID: 21932489
[No Abstract] [Full Text] [Related]
8. Prophylaxis in haemophilia patients with inhibitors.
Leissinger CA
Haemophilia; 2006 Dec; 12 Suppl 6():67-72; discussion 72-3. PubMed ID: 17123397
[TBL] [Abstract][Full Text] [Related]
9. A successful use of recombinant factor VIIa in a patient with inhibitors, for bilateral cataract operation and circumcision.
Leblebisatan G; Sasmaz I; Antmen B; Kilinc Y; Sizmaz S; Yagmur M
Haemophilia; 2006 Mar; 12(2):187-9. PubMed ID: 16476096
[No Abstract] [Full Text] [Related]
10. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F
Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
[TBL] [Abstract][Full Text] [Related]
11. Surgery-associated acquired haemophilia and response to combined rituximab and cyclosporine treatment.
Kam G; Lee YS; Tan TT; Chow P; Ng HJ
Haemophilia; 2011 Jul; 17(4):715-6. PubMed ID: 21362110
[No Abstract] [Full Text] [Related]
12. Induction of tolerance after combined immunosuppression and -adsorption in two patients with acquired haemophilia after severe haemorrhages controlled by sequential administration of rFVIIa and FEIBA.
Stockschläder M; Ruf L; Linderer A; Schroeder T; Knoefel WT; Haas R; Giers G; Gerhardt A; Sucker C; Zotz RB; Scharf RE
Thromb Haemost; 2009 Mar; 101(3):586-90. PubMed ID: 19277426
[No Abstract] [Full Text] [Related]
13. Successful eradication of inhibitor of late recurrence and other high risk prognostic factors in a patient with severe haemophilia A.
Ranta S; Koskinen S; Mäkipernaa A
Haemophilia; 2011 Sep; 17(5):e833-4. PubMed ID: 21624011
[No Abstract] [Full Text] [Related]
14. Recombinant VIIa concentrate in the management of bleeding following prothrombin complex concentrate-related myocardial infarction in patients with haemophilia and inhibitors.
Hough RE; Hampton KK; Preston FE; Channer KS; West J; Makris M
Br J Haematol; 2000 Dec; 111(3):974-9. PubMed ID: 11122162
[TBL] [Abstract][Full Text] [Related]
15. Complete immunotolerance induction after FEIBA prophylaxis in a haemophilia A patient with high-titre inhibitor.
Nanishi E; Ohga S; Doi T; Ishimura M; Ihara K; Takada H; Shima M; Hara T
Haemophilia; 2012 May; 18(3):e75-7. PubMed ID: 22404696
[No Abstract] [Full Text] [Related]
16. Bypassing agent prophylaxis for preventing arthropathy in patients with inhibitors.
Ewenstein BM; Wong WY; Schoppmann A
Haemophilia; 2010 Jan; 16(1):179-80. PubMed ID: 19702885
[No Abstract] [Full Text] [Related]
17. Sequential therapy with activated prothrombin complex concentrate (FEIBA) and recombinant factor VIIa in a patient with severe haemophilia A, inhibitor presence and refractory bleeding.
Economou M; Teli A; Tzantzaroudi A; Tsatra I; Zavitsanakis A; Athanassiou-Metaxa M
Haemophilia; 2008 Mar; 14(2):390-1. PubMed ID: 18194305
[No Abstract] [Full Text] [Related]
18. Major orthopaedic surgery for a haemophilia patient with inhibitors using a new bypassing agent.
Takedani H; Hirose J; Minamoto F; Kubota M; Kinkawa J; Noguchi M
Haemophilia; 2016 Sep; 22(5):e459-61. PubMed ID: 27456673
[No Abstract] [Full Text] [Related]
19. Promising coagulation factor VIII bypassing strategies for patients with haemophilia A.
Duan X; Tang M; Zhang J; Yu H; Xu R
Blood Coagul Fibrinolysis; 2014 Sep; 25(6):539-52. PubMed ID: 24614429
[TBL] [Abstract][Full Text] [Related]
20. Successful bleeding control with recombinant porcine factor VIII in reduced loading doses in two patients with acquired haemophilia A and failure of bypassing agent therapy.
Stemberger M; Möhnle P; Tschöp J; Ney L; Spannagl M; Reincke M
Haemophilia; 2016 Sep; 22(5):e472-4. PubMed ID: 27480782
[No Abstract] [Full Text] [Related]
[Next] [New Search]
